EXpression of the cell cycle regulators p53, p21WAF1/CIP1 and p16INK4A in human endometrial adenocarcinoma

Experimental Oncology

Volumn 28, Issue 2, 2006, Pages 152-155

  Buchynska, L G ^a   Nesina, I P ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Differentiation grade; Endometrial cancer; Ki 67; p16INK4; p21WAF1 CIP1; p53

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN P16INK4A; PROTEIN P53;

ADULT; AGED; ARTICLE; CELL CYCLE REGULATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM POLYP; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PROTEIN EXPRESSION; UTERINE CERVIX;

ADENOCARCINOMA; ADULT; AGED; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33746497797     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Kopnin BP. Targets of oncogenes and tumor-suppressors: a key for understanding basic mechanisms of carcinogenesis. Biochemistry 2000; 65: 5-33 (in Russian).
2. Ashrafyan LA, Kiselev VI, Snigereva GP, Mukhtarulina SV. The role of papilloma virus infection in ovarian cancer. Russ J Oncol 2005; (4): 50-2 (in Russian).
3. Vogelstein B, Kinzler W. The genetic basis of human cancer. McGrow-Hill Health Professinal Division, New-York, 1998; 731 p.
4. Sakuragi N, Hirai A, Tada M, Yamada H, Yamamoto R, Fujimoto S, Moriuchi T. Dominant negative mutation of p53 tumor suppresor gene in endometrial carcinoma. Gynecol Oncol 2001; 83: 485-90.
5. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK, Iacopetta BJ. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996; 27: 1050-5.
6. Ito K, Sasano H, Matsunaga G, Sato S, Vajima A, Nasim S, Garret CT. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 1997; 183: 318-24.
7. Ellinidi VN, Anikeeva NV, Maksimova NA. Practical immunocytochemistry (methodical recommendation). St-Petersburg: 2002: 36 p. (in Russian).
8. Lapach CM, Chubenko AV, Babich PM. Statistical methods for medicobiological investigations using Excel. Kyiv: Morion, 2001: 408 p. (in Russian).
9. Chumakov PM. The function of the p53 gene: a choice between life and death. Biochemistry 2000; 65: 34-47 (in Russian).
10. Ioachim E, Kitsiou E, Mitselou A, Zagorianakou N, Charalabopoulos K, Salmas M, Makrydimas G, Vougiouklakis Th, Agnantis NG. p21 (WAF1/Cip1) protein expression in normal, hyperplastic and malignant endometrium. Correlation with hormone receptor status, C-ERBB-2 oncoprotein, BCL-2 and other cell cycle related proteins (RB, P53, Ki-67, PCNA). Exp Oncol 2003; 25: 200-5.
11. Schneider-Stock R, Mawrin C, Motsch C, Boltze C, Peters B, Hartig R, Buhtz P, Giers A, Rohrbeck A, Freigang B, Roessner A. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol 2004; 164: 1233-41.
12. Spivak IM, Smirnova NV, Pleskach NM, Ledascheva TA, Mikhelson VM. Some stabilization features of p53 protein in gamma-irradiated cells of patients with ataxia-telangiectasia. Tsytology 2004; 4: 898-906 (in Russian).
13. Ganina KP, Polyshchuk LZ, Buchynska LG. Cytomorphology and cytogenetic of glandular hyperplasia and endometrial cancer. Kyiv: Naukova Dumka, 1990; 160 p. (in Russian).
14. Baranova AV, Yankovsky NK. Tumor suppressor genes. Mol Biol (Russ) 1998; 32: 206-18 (in Russian).
15. Kopnin BP. Tumor suppressor and imitator genes. In: Carcinogenesis. Zaridze DG, ed. Moskow: Medicine, 2004; 125-58 pp (in Russian).